Loading...
•
Mar 31, 2023
LifeStance Q1 2023 Earnings Report
LifeStance's Q1 2023 results reflected a mix of revenue growth and strategic investments.
Key Takeaways
LifeStance Health Group reported a 24% increase in total revenue to $252.6 million for Q1 2023. The company's net loss was $34.2 million, an improvement compared to the prior year's $62.3 million. The company is raising full year revenue and Center Margin guidance while reaffirming full year Adjusted EBITDA guidance.
Total revenue increased by 24% to $252.6 million.
Total clinicians reached 5,961, up 19% year-over-year.
Net loss was $34.2 million, primarily driven by stock-based compensation.
Adjusted EBITDA was $10.1 million.
LifeStance
LifeStance
Forward Guidance
LifeStance is raising full year revenue and Center Margin guidance, with the following outlook for 2023:
Positive Outlook
- The Company expects full year revenue of $990 million to $1.02 billion
- Center Margin of $274 to $290 million
- Adjusted EBITDA of $50 to $62 million
- For the second quarter of 2023, the Company expects total revenue of $250 to $260 million
- Center Margin of $69 to $76 million
Challenges Ahead
- The Company expects Adjusted EBITDA of $10 to $16 million for the second quarter of 2023
- We may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies
- If we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy
- Our ability to recruit new clinicians and retain existing clinicians
- If reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed